Impax launches generic Renvela
HAYWARD, Calif. — Specialty pharmaceutical company Impax Laboratories has launched its generic of Renvela (sevelamer carbonate) tablets immediately after receiving Food and Drug Administration approval. The drug is indicated to control serum phosphorus in adults and children ages 6 years and older who have chronic kidney disease and are on dialysis.
“We are pleased to receive approval of our generic version of Renvela," Impax president and CEO Paul Bisaro said. "The immediate launch of this product further enhances our generic portfolio and our commitment to provide patients with a more affordable treatment option."
Impax’s generic will be available in 800-mg dosage strength. The product had U.S. sales of approximately $1.9 billion for the 12 months ended August 2017, according to QuntilesIMS data.
The launch follows the recent announcement that Impax would be acquired by Ameal Pharmaceuticals.